Abstract. Mitochondria are crucial regulators of energy metabolism and apoptotic pathways and have been closely linked to the pathogenesis of neurodegenerative disorders. In this review we mainly focus on mitochondrial dysfunction in two of the most prevalent neurological disorders: Alzheimer's disease and Parkinson's disease. We discuss whether the role of mitochondria in those diseases should be considered primordial or secondary to other processes that eventually lead to neurodegeneration. In the case of Parkinson's disease, the role of mitochondria is quite clear and might be involved in the mechanism of this disorder. For Alzheimer's disease, the evidence in favor of such a link is more indirect, and mitochondrial dysfunction likely occurs at a later stage of the disorder.
INTRODUCTION
For many years, mitochondria were commonly believed to transmit hereditary information. Only from the 1950s onwards, when a method for isolating intact mitochondria was developed, the modern understanding of mitochondrial function was founded. Mitochondria are now considered essential organelles for life and death of a cell. They not only participate in energy conversion via oxidative phosphorylation, but also have major roles in many cellular functions, including inter-mediary metabolism, calcium buffering, regulation of signal cascades, and apoptosis regulation [1] . The development of powerful technologies, such as live-cell imaging, 3D reconstruction, and electron tomography has overruled the conventional static image of mitochondria and revealed that mitochondria are extremely dynamic organelles capable of establishing an interconnected network regulated by fusion/fission processes (reviewed in [2] ). Constant shape remodeling and subcellular trafficking of these organelles depend on the microtubules network and on motor proteins. Consequently, mitochondria may be organized into lengthy traveling chains, packed tightly into relatively stable groups, or appear in many other formations based upon the particular needs of the cell and the characteristics of its microtubular network [3] . The structure of the mitochondria is intrinsically interwoven with the performance of the organelle. Mitochondria have a dou-S256
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ble membrane that divides the organelle into a narrow intermembrane space (IMS) and a much larger internal matrix, each of which contains highly specialized proteins. The outer membrane of mitochondria contains voltage-dependent anion channels that in turn make the membrane permeable to metabolites and small peptides (3000 Da). Similarly, the inner membrane, which is highly convoluted so that a large number of invaginations called cristae are formed, also forms a barrier for most molecules thus preventing their passage. For this, the inner membrane utilizes a group of transport proteins, the TOM/TIM protein complexes (reviewed in [4] ). The mitochondrial respiratory chain is located within the inner membrane, and here oxidative phosphorylation (OXPHOS) occurs. The respiratory chain or electron transport chain (ETC) is composed by Complex I (NADH ubiquinone oxidoreductase), II (succinate ubiquinone oxidoreductase), III (ubiquinonecytochrome c reductase), and IV (cytochrome oxidase) and by the F 1 F 0 -ATP synthase, also known as complex V [1] . In a nutshell, the transport of electrons down the ETC releases favorable energy that is used by Complex I, III, and IV to pump protons from the matrix side across the inner membrane, thus creating a proton gradient (basic inside) and an electrochemical gradient (negative inside) across the IMS. This gradient is known as the mitochondrial membrane potential and is used to drive phosphorylation of ADP to ATP (ATP production) by F 1 F 0 -ATP synthase.
Albeit due to high energy demands or due to increased sensitivity to apoptosis and reactive oxygen species (ROS) production, mitochondrial diseases preferentially seem to affect only a subset of tissues, most notably muscles and neurons. In the latter, mitochondrial dysfunction leads to neurodegenerative disorders. Mitochondrial DNA (mtDNA) mutations, mutations in nuclear-encoded mitochondrial proteins, or mutated proteins localized in multiple intracellular compartments can affect mitochondrial function in those diseases (reviewed in [5] ).
For several decades, mitochondrial dysfunction has also been linked to the two most abundant neurodegenerative disorders, e.g., Alzheimer's and Parkinson's diseases. In this review, we address to what extent mitochondria are directly involved in the pathogenesis of these disorders; also, to what extent this dysfunction represents an epiphenomenon of the cell death and neuronal loss accompanying these diseases, and finally the potential role of mitochondrial dysfunction as key amplifiers of the disease process.
MITOCHONDRIAL DYSFUNCTION IN ALZHEIMER'S DISEASE
Alzheimer's disease (AD) is a devastating neurological disorder clinically characterized by impairment of cognitive function and changes in behavior and personality. Morphological hallmarks of the pathology are cortical and hippocampal atrophy, accumulation of neurofibrillary tangles mainly composed of hyperphosphorylated forms of the microtubular protein tau, and the presence of senile plaques. The major component of these plaques is the amyloid-β peptide (Aβ) in two most abundant forms, Aβ 40 and Aβ 42 .
Aβ affects mitochondrial enzymes
There is accumulating evidence from in vitro, in vivo, and human pathological tissue studies suggesting that mitochondrial abnormalities are a common event in AD. Electron microscopy analysis of mitochondria in various regions of AD brain revealed significant morphological alterations [6] . In situ hybridization to mitochondrial DNA, immunocytochemistry of cytochrome c oxidase, and electron micrographs of brain biopsies confirmed that mitochondrial abnormalities were present in AD cases [7, 8] . These studies also showed that neurons presenting increased oxidative damage in AD had increased levels of mitochondrial DNA and cytochrome c oxidase in the cytosol, which correlated with the significantly reduced number of mitochondria in these tissues. In some AD cases, the decreased cytochrome c oxidase activity was accompanied by increased free-radical generation and reduced energy metabolism [6, 9, 10] . Analysis of isolated mitochondria from AD platelets showed a decrease in cytochrome c oxidase activity and in ATP levels, while an increase in ROS was observed [11] . In addition, a decrease in mitochondrial membrane potential and reduced levels of ATP were also observed in neurons from an amyloid-β protein precursor (AβPP) transgenic mouse model [12] . These results indicated mitochondrial energy metabolism impairment, and since this transgenic mouse model did not reveal plaque deposition, the authors postulated a major role for intracellular Aβ in the observed mitochondrial dysfunction. Studies performed in PC12 and NT2 cells incubated with Aβ 25−35 and Aβ 1−42 peptides displayed reduced activity of the respiratory chain [13] [14] [15] , and Aβ appears to inhibit key mitochondrial enzymes in the brain and in isolated mitochondria, especially cytochrome c oxidase [16] [17] [18] . Decreased activity of
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these mitochondrial enzymes impair electron transport, ATP production, oxygen consumption, and mitochondrial membrane potential, leading to an increase in oxidative stress, release of cytochrome c, and finally apoptosis. However, these studies do not provide any insight in how Aβ might cause those impairments and it is not clear to what extent these observations are also valid for what occurs in the brain of patients.
Aβ interacts with mitochondrial proteins
Recent studies triggered by the finding that Aβ peptides inhibit mitochondrial respiration by causing opening of the permeability transition pore (PTP) [19, 20] , suggested that Aβ directly interacts with cyclophilin D (CypD), a PTP component that binds cyclosporine A and renders the channels more sensitive to Ca 2+ . This could theoretically provide a molecular basis for a pathogenic mechanism linking Aβ to mitochondria [21] . Unfortunately, the authors did not provide an answer to the question how Aβ would be able to reach the mitochondria, as Aβ is generated in the lumen of the secretory and recycling pathways and at the cell surface.
Additionally, a yeast two-hybrid screen identified the Aβ-binding alcohol dehydrogenase (ABAD), which is a member of the short chain dehydrogenase/reductase [22] . This interaction was validated by co-immunoprecipitation studies performed in AD patient brains and in a transgenic mouse model overexpressing AβPP/ABAD, which also manifested elevated levels of oxidative stress and impaired memory [23] . In additional overexpression studies, the interaction of Aβ with ABAD caused mitochondrial oxidative damage, increased carbonylation of mitochondrial proteins, and impaired activity of respiratory complexes [24] . Again, although intriguing, it remains to be confirmed that this interaction also occurs at the physiological level of protein expression and is indeed required for modulation of ABAD activity. Nevertheless, the origin of mitochondrial Aβ is still a matter of debate. Studies that have attempted to address this question revealed that in vitro import of Aβ 1−40 and Aβ 1−42 in isolated rat mitochondria occurs via the mitochondrial TOM machinery [25] .
HtrA2/Omi, a pro-apoptotic serine protease that is released to the cytoplasm from the mitochondria upon apoptotic stimuli [26] , is another mitochondrial protein that has been identified to interact with Aβ [27] . Overexpression studies have shown that Aβ binds to the PZD domain of HtrA2/Omi and can co-immunoprecipitate the cytosolic form of HtrA2/Omi. It is not clear whether this interaction occurs within the mitochondria or after apoptotic stimuli have caused the release of the cytosolic form of HtrA2/Omi from the mitochondria. It has also been reported that intra-mitochondrial Aβ blocks the entry of nuclear-encoded proteins into mitochondria, leading to decreased mitochondrial membrane potential, increased ROS production, oxygen glucose deprivation, and altered mitochondrial morphology [28] .
Aβ affects mitochondria morphology and transport
Another possible pathway to explain the link between Aβ and mitochondrial dysfunction is the possibility that increased ROS production activates the mitochondrial fission proteins Drp1 and Fis1, which cause mitochondrial fragmentation [29] . Mitochondrial fragmentation is observed in AD brain and can indeed be explained by oxidation of Drp-1. The latter would also lead to synapse loss [30] . Additional studies have implied a role of Aβ in modulating proteins involved in the mitochondrial fission/fusion processes as well. Overexpression of wild-type or Swedish AβPP mutant form in human neuroblastoma M17 cells show significantly decreased levels of Drp-1 and OPA1, whereas Fis1 levels were significantly upregulated [31] . Notably, overexpression of Drp-1 in these cells rescued abnormal mitochondrial distribution, while overexpression of OPA1 rescued mitochondrial fragmentation. Additional studies in hippocampal tissues of AD patients showed reduced levels of Drp-1, OPA1, Mfn1, and Mfn2, and increased levels of Fis1 [32] .
Aβ has also been reported to affect axonal transport of mitochondria. Recent studies in a Drosophila model for AD revealed depletion of presynaptic mitochondria, decreased transport of axonal mitochondria, and decreased number of synaptic vesicles [33, 34] . These studies suggested that Aβ accumulation depletes presynaptic mitochondria, and that this event preceded the change in axonal transport of mitochondria. Embryonic hippocampal neurons from rat treated with Aβ indeed showed rapid and severe impairment of mitochondrial transport [35] , further supporting the idea that Aβ can impair mitochondrial transport and consequently contributes to synaptic dysfunction. Apparently the effects of Aβ on mitochondrial function are pleiotropic and can be caused by effects on the axonal transport machinery or on the mitochondrial fission/fusion machinery. Besides Aβ-mitochondrial induced toxicity, a few reports have also linked tau protein to mitochondria dysfunction. A triple tau/AβPP/presenilin S258
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transgenic AD mouse model showed disturbed mitochondrial membrane potential and defects in the electron transport chain, as well as an increase in oxidative stress [36] . Transport of mitochondria along the axons was disturbed in the presence of isoform 3 and 4 of tau [37] . It is generally thought that the hyperphosphorylated form of tau causes toxicity in AD brain. Some reports suggest that reduced mitochondrial energy levels cause hyperphosphorylation and consequent aggregation of tau [38, 39] .
Is Aβ processed in the mitochondria?
As indicated already, it remains unclear to what extent the different proposed mechanisms really contribute to the pathogenesis of AD in patients. A major problem is the lack of a good model to explain how Aβ enters the mitochondria. Some studies have suggested that its precursor AβPP can be processed within the mitochondria. A mitochondrial presequence-like targeting sequence found behind the endoplasmatic targeting sequence has been identified in AβPP and appeared to be able to guide, under certain conditions, AβPP to the mitochondria [40] . In addition, ectopically expressed wild-type or AD-linked Swedish AβPP mutants have also been found to localize to mitochondria in different cell types. Recent studies have identified active γ-secretase complex within the inner mitochondrial membrane, containing all four members of the complex PS, NCT, Aph-1, and Pen2 [41, 42] . It should be noticed that most studies locate the γ-secretase in the membranes of organelles along the biosynthetic pathway, and more work is needed to exclude the possibility that part of the signals reflected contamination of vesicular structures in the mitochondrial preparations (it is notoriously difficult to separate mitochondria completely from ER). An additional problem is the question how γ-secretase mediated cleavage of AβPP could occur in the mitochondria [40] . More precise work is needed to precisely localize AβPP and γ-secretase and to demonstrate that protease and substrate are located in the same membrane and that their topology is compatible with γ-secretase processing of AβPP. This, along with the fact that no reports have verified the presence of functional β-secretase in this organelle, makes that at this moment one would be inclined to conclude that the observed mitochondrial toxicity caused by Aβ is likely indirect.
Also for the other reports related to Aβ associated mitochondrial toxicity, a major question remains to be addressed: the origin of the intracellular cytoplasmic Aβ. Thus, while the available evidence clearly shows that Aβ can affect mitochondrial function, the major question on how importantly the described mechanisms contribute to sporadic AD in the real patient still requires further investigation.
MITOCHONDRIAL DYSFUNCTION IN PARKINSON'S DISEASE
Parkinson's disease (PD) is a chronic progressive neurodegenerative movement disorder with a prevalence of 1.8% in individuals of 65 years and older [43] . PD is clinically characterized by motor impairments involving resting tremor, progressive rigidity, bradykinesia, and postural instability. PD pathology is characterized most prominently by loss of dopaminergic neurons in the substantia nigra pars compacta and in most cases by the formation of intraneuronal protein aggregates called Lewy bodies [44] . At the time of clinical presentation, approximately 50-70% of the dopaminergic neurons have been lost [45] and surviving neurons may present Lewy body inclusions.
Mitochondria in sporadic PD
In contrast to AD, the involvement of mitochondrial dysfunction in PD, as a direct causal factor, is reasonably well supported by observations in patients. In fact, mitochondrial involvement in PD has been postulated for many years based on observations with mitochondrial toxins, which appear to cause in human beings and experimental animals Parkinson's like syndromes. For instance, MPTP (1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine) produced PD-like symptoms in designer drug abusers [46] . Its metabolite MPP + is actively transported into dopaminergic neurons by the dopamine transporter. Within these neurons, MPP + enters the mitochondria and selectively inhibits the mitochondrial respiratory chain Complex I of the ETC [47] . Additionally, exposure to rotenone, a highly selective mitochondrial Complex I inhibitor, also reproduced behavioral and neuropathological features of PD in rats. Brain samples of PD patients were shown to display a mild defect of Complex I [48] . The mechanism of Complex I inhibition toxicity probably involves mitochondrial-induced oxidative stress, caused by the block of the mitochondrial respiratory chain [49] . Oxidative stress is the result of an imbalance between excessive production of ROS and limited antioxidant defenses. Mitochondria generate most of
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the ROS as a byproduct of oxidative phosphorylation. Nevertheless, the selective vulnerability of dopaminergic neurons to mitochondrial dysfunction remains elusive.
Mitochondria and familial PD
The recent identification of genes involved in the pathogenesis of familial forms of PD further suggests that at least a subgroup of what is called PD, could be caused by primary deficits in mitochondrial function [50] . PD mutations have been reported to occur in genes encoding for α-synuclein, DJ-1, Leucin RichRepeat Kinase (LRRK2), ubiquitin C-terminal hydrolase L1 (UCHL1), phosphatase-tensin homologue (PTEN)-induced kinase 1 (PINK1), and Parkin, as well as within the mtDNA. Mutations in the gene encoding the mitochondrial serine protease HtrA2/Omi have also been linked to PD in several families [51] [52] [53] . Some of the genes are directly involved in mitochondrial function (and dysfunction) whereas for other genes, such as LRRK2, the link is at best indirect. We discuss some salient features of the different proteins encoded by the PD genes with regard to their possible effects on mitochondrial function.
Mutations in α-synuclein, the major component of Lewy bodies, cause autosomal dominant familial PD. Recent studies have revealed that α-synuclein appears to contain an amino-terminal mitochondrial targeting sequence [54] and acidification of the cytosol or overexpression of α-synuclein itself can cause localization of the protein to mitochondria [55, 56] . Additionally, α-synuclein-null mice demonstrate increased resistance to MPTP [57] , whereas transgenic α-synuclein animal models treated with MPTP present swollen, morphological abnormal mitochondria [58] . Additionally, small oligomers of α-synuclein can lead to Ca 2+ dysregulation, and calpain, a major Ca 2+ -activated protease, can cleave α-synuclein producing a truncated form which is prone to aggregate, thus leading to formation of fibrils [59] . Overall, these observations suggest that Ca 2+ dysregulation and consequent fibril aggregation could eventually lead to alterations in the mitochondrial PTP. The PTP complex can undergo a Ca 2+ -triggered conformational change that can lead to the opening of the mitochondrial PTP, causing mitochondrial swelling and consequent rupture of the outer membrane allowing Ca 2+ to leave the mitochondria placing further stress on nearby mitochondria. The release of cell death mediators and the increased production of ROS consequently lead to neuronal cell death.
PINK1 and Parkin affect mitochondria function
The most convincing evidence for the involvement of mitochondrial dysfunction are the mutations in the mitochondrial serine/threonine kinase PINK1 (PTENinduced putative kinase 1) that cause recessive hereditary PD in several families [60, 61] . PINK1 is a highly conserved protein, containing a catalytic serine/threonine kinase domain, ubiquitously expressed in the human brain. The PINK1 kinase not only presents a mitochondrial targeting sequence, but has actually also been shown directly to localize to the mitochondria [62] . Down regulation of PINK1 expression in SH-SY5Y decreased cell viability and increased apoptosis [63] . Studies performed in Drosophila pink1 mutants resulted in loss of dopaminergic neurons, including shortened lifespan, apoptotic muscle degeneration, and male sterility [64] [65] [66] . Additionally, studies in Drosophila and in HeLa cells indicated that Pink1 deficiency leads to altered mitochondrial morphology [64] [65] [66] [67] [68] . Pink1 deficient mice reveal impaired dopamine release [69] , deficient mitochondrial respiration, and increased sensitivity to oxidative stress and to induced cytochrome c release [70, 71] , while overexpression and loss of function studies suggested an antiapoptotic activity for PINK1 [63, 72, 73] . PD-related mutations and an artificial kinase-dead mutant abolish this anti-apoptotic effect [72] . One could argue that PINK1 most probably exerts its neuroprotective effect by phosphorylating specific mitochondrial proteins. This argument was validated by the identification of three PINK1 mitochondrial substrates, i.e., the mitochondrial heat shock protein TRAP1, the proapoptotic protein Htr2a/OMI [74, 75] ,and, more recently, Parkin [76] . PINK1 has also been shown to associate with Hsp90/Cdc37 chaperones [77, 78] . Evidence that pink1 genetically interacts with the fission/fusion machinery of mitochondria has supported the hypothesis that PINK1 deficiency affects various mitochondrial functions via interference with mitochondrial dynamics [79, 80] . It should be noticed however that genetic interactions between pink1 and drp1 (dynamin related protein) or fis1, genes implicated in mitochondrial fission [81] , do not imply necessarily that pink1 is in the same molecular pathway as these proteins. Interestingly, mutant PINK1 has been shown to exacerbate mitochondrial alterations by disturbing the mitochondrial Ca 2+ fluxes, action that is promoted by mutant α-synuclein, thus suggesting a cooperative role of these two proteins [82] . An appealing finding that could explain most of the observations is the fact that the ab- sence of PINK1 leads to decreased enzymatic activity of Complex I [71] . The energy deficiency caused by this defect leads, in Drosophila neurons, to altered synaptic function. This is reflected in deficient mobilization of the reserve pool of synaptic vesicles during rapid stimulation. This deficit can be rescued by adding ATP to the synapse, confirming an energy deficit at the level of the synapse. Loss of Complex I would result in the reduction of the mitochondrial electrochemical gradient, and therefore promote the opening of the voltage dependent PTP, which can in turn cause increased cytochrome c release and cell death [83] . Reduced Complex I activity can also lead to increased levels of ROS production as found in several studies [84, 85] . Loss of Complex I in synaptic mitochondria also results in impaired ATP production, which apparently underlies the reserve pool mobilization defects during intense stimulation of the synapse [71] . Consistent with this hypothesis is the fact that ATP levels in pink1 mutant flies are reduced compared to controls [64] , providing an explanation for the neuronal defects in pink1 mutants.
The ubiquitously expressed Parkin, an E3 ubiquitin ligase, is another gene implicated in autosomal recessive PD [86] . Parkin-null mice and Parkin Drosophila mutants develop apoptotic muscle degeneration with mitochondrial pathology and decreased resistance to oxidative stress [87] [88] [89] . Reduced levels of mitochondrial proteins involved in mitochondrial oxidative phosphorylation were reported in Parkin-knockout mice, which exhibited normal brain morphology, but increased striatal extracellular dopamine levels [87] . Overexpression of Parkin in cultured cells prevents mitochondrial swelling and stress-induced apoptosis. Despite the fact that the majority of Parkin is localized to the cytosol, as the majority of the E3 ligases, some Parkin was suggested to be localized in the mitochondrial matrix, where it would enhance mitochondrial gene transcription and biogenesis in proliferating cells [90, 91] . The exact mechanism for the protective function of Parkin in mitochondria remains unknown. Similar to PINK1 mutant flies, Drosophila Parkin mutants exhibited reduced lifespan, locomotor defects resulting from apoptotic muscle degeneration and mitochondrial structural alterations [88] . Additionally, overexpression of Parkin in PC12 cells protected against ceramide-mediated cell death by delaying mitochondrial swelling and subsequent cytochrome c release and caspase 3 activation, and this protective effect was abrogated by Parkin mutants [92] . Overexpression of Parkin was shown to rescue the mitochondria dysfunction caused by PINK1 deficiency, suggesting that the two proteins could cooperate, probably by regulating the balance between mitochondrial fission and fusion, hence preserving mitochondrial integrity in various stress conditions [66, 80] . Furthermore, in a recent study it was shown that Parkin is involved in autophagy of dysfunctional mitochondria [93] , which might provide a mechanistic explanation for the genetic interaction that has been reported between Parkin and Pink1 in Drosophila [64, 66, 68] , further reinforcing the concept that Parkin has a neuroprotective role. A working hypothesis that has emerged recently is that Parkin and PINK1 act together as a "mitochondrial quality control machinery", to modulate the trafficking of defective mitochondria to the lysosome-rich perinuclear area [94] . In brief, the loss of mitochondrial membrane potential causes cytosolic Parkin to be recruited to mitochondria, and this recruitment occurs in a PINK1-mediated fashion. The tubular mitochondrial network collapses and aggregated mitochondria clusters become surrounded with autophagic vacuoles. Although Parkin genetically interacts with PINK1, Parkin-dependent ubiquitination of PINK1 or PINK1-phosphorylation of Parkin has not yet been established in this working model.
CONCLUSION/PERSPECTIVES
For PD, the connection between mitochondrial dysfunction and pathology is quite strong, especially because genetic mutations in mitochondrial proteins are causally involved in at least some forms of PD. For AD, the situation is clearly much more complicated. Nevertheless, while it is not possible to draw conclusions as to whether mitochondrial dysfunction is a potential direct pathogenic cause of certain forms of AD, one can probably safely agree that mitochondrial dysfunction does occur at some point during the disease.
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